Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mesoblast Limited ( (AU:MSB) ) has provided an update.
An independent study presented at the American Society of Hematology Annual Meeting concluded that Mesoblast’s remestemcel-L shows superior clinical outcomes compared to ruxolitinib for treating steroid-refractory acute graft versus host disease (SR-aGvHD). The study, involving 2,732 patients, highlighted remestemcel-L’s superior outcomes in complete and overall remission, as well as differences in adverse events. This finding reinforces Mesoblast’s position in the cellular medicine industry and could have significant implications for its market presence and stakeholders.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for severe and life-threatening inflammatory conditions. The company specializes in therapies derived from its proprietary mesenchymal lineage cell therapy technology platform, which targets severe inflammation by releasing anti-inflammatory factors. Mesoblast’s flagship product, Ryoncil, is the first FDA-approved mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD). The company is also advancing additional cell therapies for other inflammatory diseases and has established commercial partnerships in Japan, Europe, and China.
Average Trading Volume: 4,882,190
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.62B
See more insights into MSB stock on TipRanks’ Stock Analysis page.